Positive basophil activation test following anaphylaxis to pertuzumab and successful treatment with rapid desensitization

J Allergy Clin Immunol Pract. 2016 Mar-Apr;4(2):338-40. doi: 10.1016/j.jaip.2015.10.007. Epub 2015 Dec 24.

Authors

David González-de-Olano¹, Jose M Morgado², Raquel Juárez-Guerrero³, Laura Sánchez-Muñoz², Javier Letellez-Fernández⁴, Diego Malón-Giménez⁵, Mariana C Castells⁶

Affiliations

¹ Allergy Unit, Hospital Universitario de Fuenlabrada, Madrid, Spain. Electronic address: [email protected].
² Instituto de Estudios de Mastocitosis de Castilla La Mancha (CLMast), Hospital Virgen del Valle, Toledo, Spain.
³ Allergy Unit, Hospital Universitario de Fuenlabrada, Madrid, Spain.
⁴ Pharmacy Department, Hospital Universitario de Fuenlabrada, Madrid, Spain.
⁵ Oncology Department, Hospital Universitario de Fuenlabrada, Madrid, Spain.
⁶ Allergy and Immunology Department, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass.

PMID: 26725157
DOI: 10.1016/j.jaip.2015.10.007

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Anaphylaxis / diagnosis*
Anaphylaxis / etiology
Anaphylaxis / prevention & control
Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Basophil Degranulation Test*
Basophils / immunology*
Breast Neoplasms / diagnosis*
Breast Neoplasms / drug therapy
Desensitization, Immunologic*
Drug Hypersensitivity / diagnosis*
Drug Hypersensitivity / immunology
Drug Hypersensitivity / therapy
Female
Humans
Neoplasm Metastasis
Receptor, ErbB-2 / metabolism
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Receptor, ErbB-2
pertuzumab